Starmer’s goodbye gift to Britain: a US pharma deal that could be more lethal than Covid

Starmer’s Goodbye Gift to Britain: A US Pharma Deal More Lethal Than Covid

Starmer s goodbye gift to Britain - Starmer’s goodbye gift to Britain has sparked widespread concern. The agreement, finalized with Donald Trump, allows American pharmaceutical companies to dominate the healthcare sector, potentially worsening the crisis that the NHS was designed to combat. While the deal was presented as a strategic move to secure trade benefits, critics argue it risks undermining the very system that has long been a cornerstone of British public life. The absence of clear justification for the financial commitments and the rapid legislative process have left many questioning the decision’s long-term impact.

The Pact with Trump and Its Consequences

At the heart of the controversy is a treaty signed in December 2025 between Starmer’s Labour government and the Trump administration. In exchange for lifting tariffs on British drug exports, Downing Street committed to boosting spending on branded pharmaceuticals. This trade agreement, framed as a win for healthcare, has instead been exposed as a backdoor deal that prioritizes corporate interests. Analysts warn that the NHS, already under pressure, is now being forced to subsidize American drug companies, creating a fiscal burden that could be more damaging than the pandemic itself.

Government Opacity and Rapid Passage

The deal’s passage through Parliament highlights a troubling lack of transparency. Wes Streeting, the Health Secretary, provided minimal details on the financial implications, relying on statutory instruments to expedite the process. This method allows legislation to bypass thorough debate, giving ministers control over the timing of discussions. The law was only unveiled in the days leading up to the Easter bank holiday, with key terms published at the last minute. Critics suggest this timing was deliberate, aiming to suppress public scrutiny and minimize backlash.

“When discussing the deal with Trump, Streeting made three promises,” the researchers wrote. “First, in any negotiation, ‘the NHS is not on the table.’ Second, ‘we’re not going to cut NHS services to fund the pharma deal.’ And finally, over the next couple of years the agreement would cost ‘around £1bn’ a year.”

These assurances have since been called into question. The study published in the British Medical Journal reveals that the deal’s true cost is far greater than claimed. With drug spending increasing from 0.3% to 0.6% of national income, the NHS will face significant budget cuts. Resources currently allocated to essential services—such as cancer scans, staffing, and diabetes treatments—will be redirected to branded medications, jeopardizing patient care. The researchers estimate this shift could lead to 229,000 additional deaths by 2036, a figure they describe as conservative.

Starmer’s goodbye gift to Britain has also raised concerns about the independence of the healthcare system. By tying NHS funding to international trade deals, the government risks making the system a tool for corporate gain. The absence of public consultation and the secrecy surrounding the deal’s negotiations have fueled accusations of political negligence. With ministers prioritizing speed over scrutiny, the public remains unaware of the full scale of the financial and human toll this agreement could exact.

As the implications of the pharma deal become clearer, the contrast with recent budget proposals grows sharper. While the government has allocated funds to various sectors, the emphasis on branded drugs underscores a shift toward private interests. The study’s findings challenge the narrative that this deal is a win for healthcare, instead framing it as a concession that could erode public trust. For many, Starmer’s goodbye gift to Britain is not a symbol of progress but a warning of deeper economic and social consequences.